Novo’s late-stage IL-6 stumble shakes inflammation space
Phase 3negativeziltivekimabNegative
AI Analysis
Summary
Novo Nordisk's Phase 3 trial of ziltivekimab, an investigational IL-6 therapy intended to improve cardiovascular outcomes, failed last week. The negative result impacts not only Novo Nordisk but other drugmakers developing therapies targeting the same pathway.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 failure for ziltivekimab in cardiovascular outcomes
Importance:8/10
Sentiment:
-0.90
Phase 3 failureIL-6 inhibitorcardiovascularinflammationnegative trial result
Related Companies
Read the original article
Published by BioSpace on August 3, 2026 11:31 AM